Potential for use of Al/machine learning for pharmacovigilance: Is there a role for regulators?
British Journal of Clinical Pharmacology, EarlyView.
Christina Gao +3 more
wiley +1 more source
Abstract Aims Risk minimization measures (RMMs) are key regulatory tools to ensure safe medicinal product use. Regulatory guidelines recommend pre‐specifying the targets, or ‘thresholds’, for assessing RMM effectiveness. We aimed to review recent industry‐sponsored post‐authorization safety studies (PASS) that evaluated the effectiveness of RMMs ...
Kexin Zhu +7 more
wiley +1 more source
Two-way FDI and corporate total factor productivity--moderating role of environmental information disclosure quality. [PDF]
Duan Y, Ruan Y.
europepmc +1 more source
Reception Baseline Assessment and ‘small acts’ of micro‐resistance
Abstract In September 2021, following the global COVID‐19 pandemic, the Department for Education introduced a national standardised digital Reception Baseline Assessment (RBA) for all English 4‐year‐old children. We analyse RBA and its associated Quality Monitoring Visits, as a further intensification of the new public management of early years ...
Guy Roberts‐Holmes +2 more
wiley +1 more source
FDA-Cleared Artificial Intelligence Medical Devices in Orthopaedic Surgery. [PDF]
Lee B +5 more
europepmc +1 more source
Strategic equity compensation: A delphi-AHP approach to industry-specific governance design for RSUs. [PDF]
Park WA, Sernova E, Park CY.
europepmc +1 more source
Reconciliation or reputation: critical analysis of commercial sector commitments and framing in reconciliation action plans. [PDF]
Leersen P +4 more
europepmc +1 more source
HTA submission strategies and their associations with rollout times and type of HTA recommendation in Australia and Canada. [PDF]
Sola-Barrado B, Wang T, McAuslane N.
europepmc +1 more source
Exploring the drivers of hesitancy toward coronavirus disease 2019 vaccine among Syrian refugees residing in Mount Lebanon: A qualitative study. [PDF]
Fakih MA, Obeid L, Whaibeh E, Abbas N.
europepmc +1 more source
Entrepreneurship beyond the lab: commercializing your creative outputs. [PDF]
Martínez-Montemayor MM +2 more
europepmc +1 more source

